Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil

Clinics

Volumn 66, Issue 1, 2011, Pages 9-15

  Reis, Adriano Max Moreira ^a   Cassiani, Silvia Helena de Bortoli ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Critically ill; Drug drug interaction; Drug enteral nutrition interaction; Intensive care units

Indexed keywords

DRUG;

ADULT; AGED; ARTICLE; BRAZIL; CROSS-SECTIONAL STUDY; DRUG INTERACTION; DRUG MONITORING; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MALE; MIDDLE AGED; NONPARAMETRIC TEST; PHARMACOEPIDEMIOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS; TIME;

ADULT; AGED; BRAZIL; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PHARMACOEPIDEMIOLOGY; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 79952964019     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000100003     Document Type: Article

References (43)

1. Mouly S, Meune C, Bergmann JF. Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4 Intensive Care Med. 2009;35:417-29.
2. Cruciol-Souza JM, Thomson JC. A pharmacoepidemiologic study of drug interactions in a Brazilian teaching hospital. Clinics. 2006;61:515-20.
3. Cabrera MAS, Dip RM, Furlan MO, Rodrigues SL. Use of drugs that act on the cytochrome P450 system in the elderly. Clinics. 2009;64:273-8, doi: 10.1590/S1807-59322009000400002.
4. Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit. Focus on drug interaction Clin. Pharmacokinet. 2001; v.40,11:833-68, doi: 10.2165/00003088-200140110-00004.
5. Zagli G, Tarantini F, Bonizzoli M, Di Filippo A, Peris A, De Gaudio AR, et al. Altered pharmacology in the intensive care unit patient. Fundam Clin Pharmacol. 2008, 22:493-50, doi: 10.1111/j.1472-8206.2008.00623.x.
6. Cruciol-Souza JM, Thomson JC. Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci. 2006;9:427-33.
7. Zhou SF, Xue CC, Yu XQ, Li C Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cythocrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2008;29:687-710, doi: 10.1097/FTD.0b013e31815c16f5.
8. Mann HJ. Drug-associated disease: cytocrome P450 interactions. Crit. Care Clin. 2006; 22:329-45, doi: 10.1016/j.ccc.2006.02.004.
9. Krähenbühl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krähenbühl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007; 30:379-407, doi: 10.2165/00002018-200730050-00003.
10. Romac DR, Albertson TE. Drug interactions in the intensive are unit Clinics in Chest. Medicine. 1999,v.20:385-99.
11. Klasco RK, Moore RE Drug Reax® Greenwold Village(CO): Micromedex. 2008.
12. Barrons R. Evaluation of personal digital assistance sofware for drug interactions. Am J Health-Syst Pharm. 2004;61:380-5.
13. Vonbach P, Dubied A, Krähenbühl S Beer JH. Evaluation of frequently used drug interaction screening programs. Pharm World Sci. 2008;30: 367-74, doi: 10.1007/s11096-008-9191-x.
14. Spriet I, Meersseman W, de Hoon J, von Winckelmann S, Wilmer A, Willems L. Mini-series: II. Clinical aspects. Clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med. 2009;35:603-12, doi: 10.1007/s00134-008-1383-2.
15. Hammes JA, Pfuetzenreiter F; Silveira F Koenig A, Westphal GA. Potential drug interactions prevalence in intensive care units. Rev. Bras. Terap. Intensiva. 2008;20:349-54.
16. Lima RE, Cassiani SHB. Potential drug interactions in intensive care patients at a teaching hospital. Rev Lat Am Enfermagem. 2009;17:222-7.
17. Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT. Recommendations for the use of medications with continuous enteral nutrition Am. J. Health-Syst. Pharm. 2009;66:1317-24.
18. Williams NT. Medication administration through enteral feeding tubes. Am J Health Syst Pharm. 2008;65:2347-57, doi: 10.2146/ajhp080155.
19. Straubhaar B, Krähenbühl S, Schlienger RG. The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. Drug Saf. 2006;29:79-90, doi: 10.2165/00002018-200629010-00006.
20. Sierra P, Castillo J, Gómez M, Sorribes V, Monterde J, Castaño J. Potential and real drug interactions in critical care patients. Rev Esp Anestesiol Reanim. 1997;44:383-7.
21. Letsas KP, Efremidis M, Kounas SP, Pappas LK, Gavrielatos G, Alexanian IP, et al. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors. Clin Res Cardiol. 2009;98:208-12, doi: 10.1007/s00392-008-0741-y.
22. Gupta A, Lawrence AT, Krishnan K Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 2007; 153:891-9, doi: 10. 1016/j.ahj.2007.01.040.
23. Devlin JW, Roberts RJ. Pharmacology of commonly used analgesics and sedatives in the ICU: benzodiazepines, propofol, and opioids. Crit Care Clin. 2009;25:431-49, doi: 10.1016/j.ccc.2009.03.003.
24. Schweickert WD, Kress JP. Strategies to optimize analgesia and sedation. Crit Care. 2008; 12 Suppl 3:S6.
25. Manitpisitkul W, McCann E, Lee S. Drug interactions in transplant patients: what everyone should know. Curr Opin Nephrol Hypertens. 2009;18:404-11, doi: 10.1097/MNH.0b013e32832edcb2.
26. Scaglione F, Paraboni L. Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens. Int J Antimicrob Agents. 2008; 32:294-301, doi: 10.1016/j. ijantimicag.2008.03.015.
27. Granowitz EV, Brown RB. Antibiotic adverse reactions and drug interactions. Crit Care Clin. 2008;24:421-42, doi: 10.1016/j.ccc.2007.12.011.
28. Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, Hess L, Schlienger RG, Krähenbühl S. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf. 2005;28:263-75, doi: 10.2165/00002018-200528030-00007.
29. Amariles P, Giraldo NA, Faus MJ. Clinical relevance of drug interactions. Med Clin. 129:27-35, doi: 10.1157/13106681.
30. Fuhr U. Improvement in the handling of drug-drug interactions. Eur J Clin Pharmacol. 2008; 64:167-71, doi: 10.1007/s00228-007-0436-8.
31. Hansten, P.D. Drug interaction management. Pharm. World Sci 2003;25(3):94-97, doi: 10.1023/A:1024077018902.
32. Devlin JW. The pharmacology of oversedation in mechanically ventilated adults. Curr Opin Crit Care. 2008;14:403-7, doi: 10.1097/MCC. 0b013e32830280b3.
33. Riker RR, Fraser GL. Altering intensive care sedation paradigms to improve patient outcomes. Crit Care Clin. 2009;25:527-38, doi: 10.1016/j. ccc.2009.05.004.
34. Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol. 2003;58:773-7.
35. Indermitte J, Burkolter S, Drewe J, Krähenbühl S, Hersberger KE. Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients. Drug Saf. 2007;30:71-80, doi: 10. 2165/00002018-200730010-00007.
36. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-51, doi: 10. 1056/NEJMoa040135.
37. Henz S, Maeder MT, Huber S, Schmid M, Loher M, Fehr T. Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions. Nephrol Dial Transplant. 2008;23:3939-45, doi: 10. 1093/ndt/gfn380.
38. Vonbach P, Dubied A, Krähenbühl S, Behr JH. Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med. 2008;19:413-20, doi: 10.1016/j.ejim. 2007.12.002.
39. ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066-78, doi: 10.1056/NEJMoa0901301.
40. Mehta S.R. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358.527-33, doi: 10.1016/S0140-6736(01)05701-4.
41. Levêque D, Lemachatti J, Nivoix Y, Coliat P, Santucci R, Ubeaud-Séquier G, et al. Mécanismes des interactions médicamenteuses d'origine pharmacocinétique Rev Med Interne. 2009 Sep 7. [Epub ahead of print]
42. Collins R, Peto R, Baigent C Sleight. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med. 1997;336:847-60, doi: 10.1056/NEJM199703203361207.
43. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA. 1996;276:811-5, doi: 10.1001/jama.276.10.811.